Spots Global Cancer Trial Database for esophagogastric junction carcinoma
Every month we try and update this database with for esophagogastric junction carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Cancer of Esophagogastric Junction: Optimized Sweet Versus Ivor-Lewis | NCT06162767 | Esophagogastric... | Esophagectomy b... Esophagectomy b... | 18 Years - 80 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study | NCT03933449 | Esophageal Carc... Esophagogastric... | pembrolizumab paclitaxel docetaxel irinotecan | 18 Years - | Merck Sharp & Dohme LLC | |
Cancer of Esophagogastric Junction: Optimized Sweet Versus Ivor-Lewis | NCT06162767 | Esophagogastric... | Esophagectomy b... Esophagectomy b... | 18 Years - 80 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study | NCT03933449 | Esophageal Carc... Esophagogastric... | pembrolizumab paclitaxel docetaxel irinotecan | 18 Years - | Merck Sharp & Dohme LLC |